Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Facioscapulohumeral muscular dystrophy region gene 1 protein (FRG1)
- Target
- FRG1
- Molecular classification
- Other (nuclear and cytoplasmic actin-bundling and RNA-binding protein)
01
Overview
Facioscapulohumeral muscular dystrophy region gene 1 protein (FRG1) is a highly conserved nuclear and cytoplasmic protein with additional localization to the sarcomere in skeletal muscle. It binds mRNA and actin filaments, suggesting central roles in RNA biogenesis, mRNA transport, and cytoskeletal organization. FRG1 regulates muscle and vascular development, and its overexpression or knockdown in animal models leads to muscular and vascular defects. FRG1's dysregulation is implicated in facioscapulohumeral muscular dystrophy (FSHD), where it is a strong candidate gene. Abnormal FRG1 expression can also affect angiogenesis, cell migration, and tumor progression, and it may function as a tumor suppressor through repression of migration and invasion in cell models. Despite significant research, the precise molecular mechanisms and therapeutic targeting of FRG1 are not fully established, and there are currently no approved drugs that specifically target FRG1.
- Other names
- Protein FRG1FSG1FRG1AFSHD region gene 1 proteinfacioscapulohumeral muscular dystrophy region gene-1
02
Biological functions
RNA binding and transportPre-mRNA splicing regulationActin filament binding and bundlingMuscle and vascular developmentRegulation of angiogenesis and cell migration
03
Disease associations
Muscular dystrophy (specifically facioscapulohumeral muscular dystrophy)Possible tumor suppressor function (evidence from tumor progression and angiogenesis)
04
Safety considerations
Altered FRG1 expression has effects on muscle and vascular development, suggesting that modulation may have unintended consequences for these systems
Beyond the preview
Go deeper on Facioscapulohumeral muscular dystrophy region gene 1 protein (FRG1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Facioscapulohumeral muscular dystrophy region gene 1 protein (FRG1).